BioNTech SE

ISIN US09075V1026

WKN A2PSR2

Marktkapitalisatie (in EUR)

19.920 m

Land

Duitsland

Sector

Gezondheidszorg

Dividendrendement

0,00%

Overzicht

Koers

Beschrijving

BioNTech SE is een immunotherapiebedrijf dat zich bezighoudt met therapieën voor kanker en andere ernstige ziekten. De productpijplijn omvat BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T-cellen, TCR's en Next-Gen CP-immunomodulatoren. Het bedrijf werd op 2 juni 2008 opgericht door Christopher Huber, Oezlem Tuereci en Ugur Sahin en heeft zijn hoofdkantoor in Mainz, Duitsland.

Toon meer Toon minder

Gezondheidszorg Biofarmaceutica Niet-SysteemspecifiekeÂ Biofarmaceutica Duitsland

Grafiek

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR	19.920 m
WPA, EUR	-5,07
KBV	1,1
K/W	159,5
Dividendrendement	0,00%

Winst- en verliesrekening (2025)

Omzet, EUR	2.871 m
Netto-inkomen, EUR	-1.137 m
Winstmarge	-39,59%

In welke ETF zit BioNTech SE?

Er zijn 5 ETF's die BioNTech SE bevatten. Al deze ETF's staan in de tabel hieronder. De ETF met de grootste weging van BioNTech SE is de iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).

ETF	Weging	Investeringsfocus	Fondsgrootte (in m EUR)
iShares STOXX Europe Equity Multifactor UCITS ETF EUR (Dist)	0,03%	Aandelen Europa Multi-factorstrategie	192
Goldman Sachs Paris-Aligned Climate World Equity UCITS ETF USD (Acc)	0,05%	Aandelen Wereld Sociaal/Milieu Klimaatverandering	8
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)	0,81%	Aandelen Verenigde Staten Gezondheidszorg Biotech	47
Amundi Prime Eurozone UCITS ETF DR (D)	0,14%	Aandelen Europa	73
Amundi Prime Europe UCITS ETF DR (D)	0,07%	Aandelen Europa	228

Prestaties

Rendementsoverzicht

YTD	-3,11%
1 maand	-4,31%
3 maanden	-11,70%
6 maanden	-12,19%
1 jaar	-6,78%
3 jaar	-18,75%
5 jaar	-47,38%
Since inception	+532,02%
2025	-24,98%
2024	+13,87%
2023	-33,67%
2022	-33,06%

Maandelijks rendement in een heat map

Risico

Risk metrics in this section:

Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.

ETF-rendementen zijn inclusief dividenduitkeringen (indien van toepassing).